HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Krebs-Henseleit solution

contains Na, K, Cl, Ca, MgSO4, HCO3, PO4, glucose, albumin, and tromethamine (THAM); compare to University of Wisconsin solution
Also Known As:
KHB solution; Krebs-Henseleit buffer
Networked: 285 relevant articles (8 outcomes, 11 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1. Kim, Suhn Hee: 5 articles (01/2021 - 08/2012)
2. Park, Byung Mun: 5 articles (01/2021 - 08/2012)
3. Najafi, Moslem: 4 articles (06/2018 - 01/2012)
4. Essop, M Faadiel: 4 articles (01/2017 - 01/2012)
5. Angelos, Mark G: 4 articles (09/2007 - 02/2002)
6. Kuppusamy, Periannan: 4 articles (09/2007 - 01/2006)
7. Hochhauser, E: 4 articles (10/2005 - 11/2001)
8. Vidne, B A: 4 articles (10/2005 - 11/2001)
9. Bunte, Sebastian: 3 articles (01/2020 - 01/2018)
10. Heinen, André: 3 articles (01/2020 - 01/2018)

Related Diseases

1. Ischemia
2. Hypoxia (Hypoxemia)
3. Infarction (Infarctions)
01/01/2020 - "RBCs from young and healthy volunteers as well as from aged persons and elderly diabetes patients with satisfying blood glucose control improved left ventricular function upon 60 min of reperfusion with Krebs-Henseleit buffer and reduced the infarct size compared to buffer treated controls. "
01/01/2022 - "Sprague Dawley rat hearts subjected to 25 minutes of in vivo ischemia (DCD hearts), or control beating donor hearts, were treated with AMO or vehicle for the first 5 minutes of reperfusion, followed by Krebs-Henseleit buffer reperfusion for 55 minutes (for mitochondrial isolation) or 85 minutes (for infarct size determination). "
03/01/2014 - "We employed several experimental systems: (i) Isolated rat hearts were perfused ex vivo with Krebs-Henseleit buffer containing 33 mm glucose vs. controls (11 mm glucose) ± global ischaemia and reperfusion ± BFT (first 20 min of reperfusion); (ii) Infarct size determination as per the ischaemic protocol, but with regional ischaemia and reperfusion ± BFT treatment; in separate experiments, NOGP inhibitors were also employed for (i) and (ii); and (iii) In vivo coronary ligations performed on streptozotocin-treated rats ± BFT treatment (early reperfusion). "
01/01/2009 - "Left ventricular (LV) function, creatine kinase (CK) and lipid peroxide products (LPOP = oxidant stress), as well as the area at risk (AAR), and infarct size (IS) after reperfusion were studied in 3 groups of isolated rat hearts perfused with Krebs Henseleit Buffer (KHB)-stabilized isolated rat hearts that were subjected to 20 minutes(') of global ischemia at 37 degrees C followed by 60' of reperfusion with KHB: Hearts were perfused with TA containing KHB for 10' just prior to ischemia or during the first 10' of reperfusion. "
4. Ventricular Fibrillation
5. Heart Arrest (Cardiac Arrest)

Related Drugs and Biologics

1. Cardioplegic Solutions
2. Adenosine (Adenocard)
3. Solutions
4. Oxygen (Dioxygen)
5. Nitrogen
6. Carbon Dioxide
7. Phosphates (Orthophosphate)
8. Glucose (Dextrose)
9. Buffers
10. Glutathione (Reduced Glutathione)

Related Therapies and Procedures

1. Induced Heart Arrest (Cardioplegia)
2. Glycemic Control
3. Thoracotomy
4. Ligation
5. Uterine Myomectomy